Fatal Pancytopenia Associated with the Use of Captopril

Brief Reports1 January 1981Fatal Pancytopenia Associated with the Use of CaptoprilIRENE GAVRAS, M. D., LOUIS G. GRAFF, M.D., BURTON D. ROSE, M.D., JOHN M. McKENNA, M.D., HANS R. BRUNNER, M.D., HARALAMBOS GAVRAS, M.D.IRENE GAVRAS, M. D., LOUIS G. GRAFF, M.D., BURTON D. ROSE, M.D., JOHN M. McKENNA, M.D., HANS R. BRUNNER, M.D., HARALAMBOS GAVRAS, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-1-58 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptChronic inhibition of the angiotensin-converting enzyme has been used successfully in treating hypertension and congestive cardiac failure (1-4) over the past 3 years. The only oral angiotensin-converting enzyme inhibitor presently available for clinical use, captopril (Capoten, E. R. Squibb & Sons, Inc., Princeton, New Jersey), has been associated with a number of adverse reactions. These include skin rashes, sometimes preceded by fever, often accompanied by eosinophilia and lymphopenia; proteinuria, usually observed in patients with primary renal parenchymal disease; alteration or loss of taste; and recently, four cases of leukopenia with agranulocytosis (5-8). All these were transient and reversible by decreasing...References1. GAVRASBRUNNERTURINI HHG. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978, 298:991-5. CrossrefMedlineGoogle Scholar2. BRUNNERGAVRASWAEBER HHB. Oral angiotensin-converting enzyme inhibitor in long-term treatment of hypertensive patients. Ann Intern Med. 1979;90:19-23. LinkGoogle Scholar3. DAVISRIBNERKEUNGSONNENBLICKLEJEMTEL RHEET. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979;301:117-21. CrossrefMedlineGoogle Scholar4. TURINIBRUNNERGRIBICWAEBERGAVRAS GHMBH. Improvement of chronic congestive heart failure by oral captopril. Lancet. 1979;1:1213-5. CrossrefMedlineGoogle Scholar5. VAN BRUMMELENWILLEMZETANTHOMPSON PRWJ. Captopril-associated agranulocytosis. Lancet. 1980;1:150. Letter. CrossrefMedlineGoogle Scholar6. AMANNBÜHLERCONENBRUNNERRITZSPECK FFDFRB. Captopril-associated agranulocytosis. Lancet. 1980; 1:150. Letter. MedlineGoogle Scholar7. STAESSENFAGARDLIFNENAMERY JRRA. Captopril and agranulocytosis. Lancet. 1980;1:926-7. CrossrefMedlineGoogle Scholar8. ELIJOVIHKRAKOFF FL. Captopril associated granulocytopenia in hypertension after renal transplantation. Lancet. 1980;1:928-9. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston City Hospital Boston, Massachusetts Saint Vincent Hospital Worcester, Massachusetts PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLarge-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effectsErythropoietin Regulation by Angiotensin IIResponse to Moulder et al., "Re: Davis et al., 'Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation'"Captopril modulates hypoxia-inducible factors and erythropoietin responses in a murine model of total body irradiationTiming of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiationA Role for Angiotensin‐Converting Enzyme in the Characterization, Enrichment, and Proliferation Potential of Adult Murine Pituitary Colony‐Forming Cells1-(D-3-Mercapto-2-Methyl-1-Oxopropyl)-L-Proline (S,s) 62571-86-2Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cellsAngiotensin-Converting Enzyme Inhibitor Promotes Coronary Collateral Circulation in Patients With Coronary Artery DiseaseCaptopril Inhibits the Proliferation of Hematopoietic Stem and Progenitor Cells in Murine Long‐Term Bone Marrow CulturesTissue Inhibition of Angiotensin-Converting Enzyme Activity Stimulates Angiogenesis In VivoCongestive Heart FailureDose-response relationships with antihypertensive drugsThe Role of Leukocyte-Generated Reactive Metabolites in the Pathogenesis of Ideosyncratic Drug ReactionsCaptopril-Associated Aplastic AnemiaCaptopril and Aplastic AnemiaChoong R. Kim, MD, Meighan B. Maley, Pharm D, Emile R. Mohler Jr., MDAngiotensin Converting Enzyme Inhibitors as Antihypertensive TherapyAngiotensin converting enzyme inhibitors. Properties and side effects.Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapyCaptopril in severe childhood hypertension—Reversible anaemia with high dosageAdverse Reactions with Angiotensin Converting Enzyme (ACE) InhibitorsHemodynamic and metabolic effects of enalapril in patients with heart failureUse of Captopril as Early Therapy for Renal Scleroderma: A Prospective StudyCaptopril for Refractory Hypertension in Patients with Impaired Renal FunctionA parallel study of enalapril and captopril and 1 year of experience with enalapril treatment in moderate-to-severe essential hypertensionCaptopril-Associated Cholestatic JaundiceJAVED RAHMAT, M.D., RICHARD L. GELFAND, M.D., MICHAEL C. GELFAND, M.D., JAMES F. WINCHESTER, M.D., GEORGE E. SCHREINER, M.D., HYMAN J. ZIMMERMAN, M.D.Essential hypertension: Psychiatric aspects and use of psychotropicsEnalapril (MK-421), A New Angiotensin-Converting Enzyme InhibitorLow-dose captopril for the treatment of mild to moderate hypertension.Low-dose captopril titration in patients with moderate-to-severe hypertension treated with diuretics.Drugs and the KidneyAntihypertensive drugsLow-dose captopril in the treatment of severe refractory hypertension associated with renal failureLong-term experience with captopril in severe hypertension.Captopril: Clinical Pharmacology and Benefit-to-Risk Ratio in Hypertension and Congestive Heart FailureInhibitors of the Renin-Angiotensin System as Antihypertensive AgentsHypotensive drugsCaptopril-Induced Granulocyte Aggregation. A Possible Complement Mediated Mechanism of Peripheral LeukopeniaEffects of the New Oral Angiotensin Converting Enzyme Inhibitor MK-421 In Human HypertensionCaptopril (Capoten®, E.R. Squibb & Sons)Safety and Efficacy of Chronic Therapy with Captopril in Hypertensive Patients: An UpdateCaptopril in the Treatment of HypertensionHARALAMBOS GAVRAS, M.D., HANS R. BRUNNER, M.D., IRENE GAVRAS, M.D.ANTIHYPERTENSIVE EFFECT OF THE NEW ORAL ANGIOTENSIN CONVERTING ENZYME INHIBITOR "MK-421".MECHANISM OF ACTION OF CLOFIBRATESUCCESSFUL LOW DOSE CAPTOPRIL RECHALLENGE FOLLOWING DRUG-INDUCED LEUCOPENIA 1 January 1981Volume 94, Issue 1Page: 58-59KeywordsAngiotensin converting enzyme inhibitorEosinophiliaFeversHeart failureHypertensionLymphopeniaProteinuriaRashesRenal diseasesTaste Issue Published: 1 January 1981 PDF DownloadLoading ...